Testing a one-time treatment for newly diagnosed type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new one-time treatment called CARC-101C for people recently diagnosed with type 1 diabetes. It aims to see if this treatment can help preserve the body's ability to make insulin and improve blood sugar control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 40 years old
- You were diagnosed with type 1 diabetes within the last 3 to 6 months and have certain antibodies in your blood that confirm it is autoimmune
- You are currently using insulin, and your blood sugar control (HbA1c) is between 7% and 12%
- Your body mass index (BMI) is between 18 and 35
- Your body still makes at least a small amount of insulin (measured by C-peptide test)
- You are willing to use effective birth control during the study if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
This trial tests a new cell injection (CNK-UT009) for adults with type 1 diabetes. The goal is to see if it can help manage blood sugar and reduce insulin needs.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
This study tests a new immune therapy using your own modified cells to try to stop type 1 diabetes from getting worse. It is for young adults who were recently diagnosed and still make some insulin.
This study tests a new medication, MTX228, to see if it can help people with type 1 diabetes who still make some insulin. It may slow the loss of your own insulin production and improve blood sugar control.
This trial tests an investigational drug that may help preserve the body's ability to make insulin in people with type 1 diabetes. It aims to slow the progression of the disease and reduce the need for insulin injections.
Hear when a new Autoimmune Type 1 Diabetes Mellitus(T1DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.